IN2014CN04401A - - Google Patents

Info

Publication number
IN2014CN04401A
IN2014CN04401A IN4401CHN2014A IN2014CN04401A IN 2014CN04401 A IN2014CN04401 A IN 2014CN04401A IN 4401CHN2014 A IN4401CHN2014 A IN 4401CHN2014A IN 2014CN04401 A IN2014CN04401 A IN 2014CN04401A
Authority
IN
India
Prior art keywords
compounds
treatment
glp
obesity
mediate
Prior art date
Application number
Inventor
Dieter Wolfgang Hamprecht
Jakob Lind Tolborg
Ditte Riber
Original Assignee
Zealand Pharma As
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zealand Pharma As, Boehringer Ingelheim Int filed Critical Zealand Pharma As
Publication of IN2014CN04401A publication Critical patent/IN2014CN04401A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

The invention provides glucagon analogue peptides and their use for promoting weight loss or preventing weight gain and the treatment of obesity or excess body weight and associated conditions. The compounds may also be used to improve glycemic control and/or for the treatment of diabetes. The compounds may mediate their effect inter alia by having increased selectivity for the GLP 1 receptor as compared to human glucagon.
IN4401CHN2014 2011-12-23 2012-12-19 IN2014CN04401A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161579888P 2011-12-23 2011-12-23
PCT/EP2012/076137 WO2013092703A2 (en) 2011-12-23 2012-12-19 Glucagon analogues

Publications (1)

Publication Number Publication Date
IN2014CN04401A true IN2014CN04401A (en) 2015-09-04

Family

ID=47594620

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4401CHN2014 IN2014CN04401A (en) 2011-12-23 2012-12-19

Country Status (20)

Country Link
US (2) US20130316941A1 (en)
EP (1) EP2793931A2 (en)
JP (1) JP2015502380A (en)
KR (1) KR20140114845A (en)
CN (1) CN104144696A (en)
AP (2) AP2014007797A0 (en)
AU (1) AU2012357739A1 (en)
BR (1) BR112014015681A2 (en)
CA (1) CA2858949A1 (en)
EA (1) EA201490982A1 (en)
HK (1) HK1200369A1 (en)
IL (1) IL232800A0 (en)
IN (1) IN2014CN04401A (en)
MA (1) MA35864B1 (en)
MX (1) MX2014007120A (en)
PE (1) PE20142113A1 (en)
PH (1) PH12014501336A1 (en)
SG (1) SG11201403377QA (en)
TN (1) TN2014000224A1 (en)
WO (1) WO2013092703A2 (en)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP3329A (en) 2009-07-13 2015-06-30 Zealand Pharma As Acylated glucagon analogues
UY33462A (en) 2010-06-23 2012-01-31 Zealand Pharma As GLUCAGON ANALOGS
AP2013006671A0 (en) 2010-06-24 2013-01-31 Zealand Pharma As Glucagon analogues
AR090937A1 (en) 2012-05-03 2014-12-17 Zealand Pharma As GIP-GLP-1 DUAL AGONIST COMPOUNDS AND METHODS FOR USE
EP2664374A1 (en) * 2012-05-15 2013-11-20 F. Hoffmann-La Roche AG Lysin-glutamic acid dipeptide derivatives
CN109456400A (en) 2012-07-23 2019-03-12 西兰制药公司 Glucagon analogue
TWI608013B (en) 2012-09-17 2017-12-11 西蘭製藥公司 Glucagon analogues
UA116217C2 (en) 2012-10-09 2018-02-26 Санофі Exendin-4 derivatives as dual glp1/glucagon agonists
WO2014096150A1 (en) 2012-12-21 2014-06-26 Sanofi Dual glp1/gip or trigonal glp1/gip/glucagon agonists
GB201315335D0 (en) 2013-08-29 2013-10-09 Of Singapore Amino diacids containing peptide modifiers
PT3057984T (en) 2013-10-17 2018-10-24 Boehringer Ingelheim Int Acylated glucagon analogues
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
CN105849122B (en) 2013-11-06 2021-04-30 西兰制药公司 GIP-GLP-1 dual agonist compounds and methods
CA2929107C (en) 2013-11-06 2023-09-26 Zealand Pharma A/S Glucagon-glp-1-gip triple agonist compounds
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
TW201609795A (en) 2013-12-13 2016-03-16 賽諾菲公司 EXENDIN-4 peptide analogues as dual GLP-1/GIP receptor agonists
TW201625670A (en) 2014-04-07 2016-07-16 賽諾菲公司 Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4
TW201625669A (en) 2014-04-07 2016-07-16 賽諾菲公司 Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4
TW201625668A (en) 2014-04-07 2016-07-16 賽諾菲公司 Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
EP3985016A1 (en) 2014-10-29 2022-04-20 Zealand Pharma A/S Gip agonist compounds and methods
JOP20200119A1 (en) * 2015-01-09 2017-06-16 Lilly Co Eli Gip and glp-1 co-agonist compounds
MY175669A (en) 2015-02-17 2020-07-03 Lilly Co Eli Nasal powder formulation for treatment of hypoglycemia
AR103954A1 (en) 2015-03-18 2017-06-14 Zealand Pharma As AMILINE ANALOGS
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
US10336802B2 (en) * 2015-04-16 2019-07-02 Zealand Pharma A/S Acylated glucagon analogue
AR105319A1 (en) 2015-06-05 2017-09-27 Sanofi Sa PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR
WO2016198628A1 (en) 2015-06-12 2016-12-15 Sanofi Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
TW201706291A (en) 2015-07-10 2017-02-16 賽諾菲公司 New EXENDIN-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists
TWI622596B (en) * 2015-10-26 2018-05-01 美國禮來大藥廠 Glucagon receptor agonists
WO2017214543A1 (en) 2016-06-09 2017-12-14 Amidebio, Llc Glucagon analogs and methods of use thereof
PL3494120T3 (en) 2016-08-05 2021-09-20 Boehringer Ingelheim International Gmbh Oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors
AR109514A1 (en) 2016-09-09 2018-12-19 Zealand Pharma As AMILINE ANALOGS
BR112019010624A2 (en) * 2016-12-09 2019-10-22 Zealand Pharma As double acylated glp-1 / glp-2 agonists and composition
CN111094331B (en) * 2017-08-16 2024-03-29 东亚St株式会社 Acylated oxyntomodulin peptide analogues
MX2020008116A (en) 2018-02-02 2020-09-25 Boehringer Ingelheim Int Heterocyclyl-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors.
EP3746449B1 (en) 2018-02-02 2022-03-30 Boehringer Ingelheim International GmbH Pyrazole- and indazole-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors
MX2020007994A (en) 2018-02-02 2020-09-09 Boehringer Ingelheim Int Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors.
PE20210174A1 (en) 2018-02-02 2021-01-29 Boehringer Ingelheim Int OXADIAZOLOPYRIDINE DERIVATIVES SUBSTITUTED WITH BENZYL, (PYRIDIN-3-IL) METHYL OR (PYRIDIN-4-IL) METHYL AS INHIBITORS OF GHRELIN O-ACYLTRANSFERASE (GOAT)
CN111349155B (en) * 2018-12-24 2022-04-05 浙江和泽医药科技股份有限公司 Glucagon analogue and preparation method and application thereof
TWI771669B (en) 2019-04-26 2022-07-21 美商美國禮來大藥廠 Method for preparing stable peptide formulations
AU2020384729A1 (en) 2019-11-11 2022-04-14 Boehringer Ingelheim International Gmbh NPY2 receptor agonists
WO2021233882A1 (en) 2020-05-22 2021-11-25 Boehringer Ingelheim International Gmbh Process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate
CN113278060B (en) * 2020-05-29 2022-03-25 东莞云璟生物技术有限公司 GLP-1/glucagon dual agonist fusion proteins
WO2022029231A1 (en) 2020-08-07 2022-02-10 Boehringer Ingelheim International Gmbh Soluble npy2 receptor agonists

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE290014T1 (en) 1996-09-09 2005-03-15 Zealand Pharma As SOLID PHASE PEPTIDE SYNTHESIS
IL138214A0 (en) 1998-03-09 2001-10-31 Zealand Pharmaceuticals As Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
WO2006134340A2 (en) 2005-06-13 2006-12-21 Imperial Innovations Limited Oxyntomodulin analogues and their effects on feeding behaviour
US7928058B2 (en) 2006-02-22 2011-04-19 Merck Sharp & Dohme Corp. Pharmaceutical composition comprising oxyntomodulin derivatives and a method for reducing body weight using the composition
CN101622276B (en) 2006-07-18 2015-04-22 赛诺菲-安万特 Antagonist antibody against EphA2 for the treatment of cancer
KR20090119876A (en) 2007-02-15 2009-11-20 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Glucagon/glp-1 receptor co-agonists
ATE520714T1 (en) 2007-06-15 2011-09-15 Zealand Pharma As GLUCAGON ANALOGUE
PA8830501A1 (en) 2008-06-17 2010-07-27 Univ Indiana Res & Tech Corp GLUCAGON / GLP-1 RECEIVER CO-AGONISTS
WO2009155257A1 (en) 2008-06-17 2009-12-23 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability physiological ph buffers
CN102292348B (en) * 2008-12-15 2015-07-08 西兰制药公司 Glucagon analogues
AP3329A (en) * 2009-07-13 2015-06-30 Zealand Pharma As Acylated glucagon analogues
CN102892425A (en) * 2010-01-20 2013-01-23 西兰制药公司 Treatment of cardiac conditions
UY33462A (en) * 2010-06-23 2012-01-31 Zealand Pharma As GLUCAGON ANALOGS

Also Published As

Publication number Publication date
US20130316941A1 (en) 2013-11-28
MA35864B1 (en) 2014-12-01
WO2013092703A3 (en) 2013-11-14
SG11201403377QA (en) 2014-07-30
WO2013092703A2 (en) 2013-06-27
AP2014007797A0 (en) 2014-07-31
AP2014007774A0 (en) 2014-07-31
BR112014015681A2 (en) 2019-09-24
PH12014501336A1 (en) 2014-09-15
EA201490982A1 (en) 2015-01-30
KR20140114845A (en) 2014-09-29
JP2015502380A (en) 2015-01-22
CA2858949A1 (en) 2013-06-27
EP2793931A2 (en) 2014-10-29
TN2014000224A1 (en) 2015-09-30
PE20142113A1 (en) 2014-12-03
HK1200369A1 (en) 2015-10-09
MX2014007120A (en) 2015-03-05
US20160347813A1 (en) 2016-12-01
IL232800A0 (en) 2014-07-31
CN104144696A (en) 2014-11-12
AU2012357739A1 (en) 2014-07-03

Similar Documents

Publication Publication Date Title
IN2014CN04401A (en)
PH12015500531A1 (en) Glucagon analogues
PH12016500675A1 (en) Acylated glucagon analogues
MX2016004907A (en) Glucagon analogues.
MY188182A (en) Acylated glucagon analogues
TN2012000560A1 (en) Glucagon analogues
TN2012000567A1 (en) Glucagon analogues
MY160219A (en) Glucagon analogues
MX2011006315A (en) Glucagon analogues.
MX2011006320A (en) Glucagon analogues.
MX2011006314A (en) Glucagon analogues.
MX2017012864A (en) Acylated glucagon analogue.
MX2016013243A (en) Peptidic dual glp-1 / glucagon receptor agonists derived from exendin-4.
MX2016013244A (en) Exendin-4 derivatives as peptidic dual glp-1 / glucagon receptor agonists.
MX2014015423A (en) Exendin-4 peptide analogues.
MX2015015249A (en) Therapeutic peptides.
TN2011000667A1 (en) Acylated glucagon analogues